Colorectal cancer metastatic disease progression in Australia: A population-based analysis |
| |
| Institution: | 1. Cancer Research Division, Cancer Council NSW, Sydney, Australia;2. Sydney School of Public Health, University of Sydney, Sydney, Australia;3. School of Medicine and Public Health, University of Newcastle, Newcastle, Australia;1. Cancer Control and Population Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, United States;2. Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Utah School of Medicine, Salt Lake City, UT 84113, United States;3. Department of Institutional Research and Reporting, Salt Lake Community College, Salt Lake City, UT 84123, United States;4. Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX 77555, United States;5. Department of Pediatric Hematology/Oncology, Salt Lake City Primary Children’s Hospital, UT 84132, United States;6. Division of Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, United States;1. Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, United States;2. Harvard Medical School, Boston, MA, United States;3. Kaiser Permanente Colorado, Institute for Health Research, Denver, CO, United States;4. Kaiser Permanente Center for Health Research, Portland, OR, United States;5. School of Public Health, University of Washington, Seattle, WA, United States;1. Research Unit for General Practice, Department of Public Health, Aarhus University, Bartholins Allé 2, 8000 Aarhus C, Denmark;2. Research Centre for Cancer Diagnosis in Primary Care, Department of Public Health, Aarhus University, Bartholins Allé 2, 8000 Aarhus C, Denmark;3. Diagnostic Centre, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Falkevej 1-3, 8600 Silkeborg, Denmark;4. Cancer Epidemiology and Population Health, King’s College London, Great Maze Pond, London SE1 9RT, United Kingdom;1. Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, 650-8507, Japan;2. Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, 650-8501, Japan;1. Department of Epidemiology and Health Statistics, School of Public Health, Zhejiang University, Hangzhou, China;2. Group of Molecular Epidemiology & Cancer Precision Prevention (GMECPP), Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences (ZJAMS), Hangzhou, China;3. Xiamen Second Hospital, Xiamen, China;4. Jiashan Institute of Cancer Prevention and Treatment, Zhejiang Province, China;1. University of Hawaii Cancer Center, Honolulu, HI, 9613, USA;2. CESP Inserm, Villejuif, France;3. Gustave Roussy, Villejuif, F-94805, France;4. Centre for Epidemiology and Biostatistics, Melbourne, VIC, Australia;5. Department of Clinical and Experimental Medicine, University of Pisa, Italy |
| |
| Abstract: | BackgroundNo previous Australian population-based studies have described or quantified the progression of colorectal cancer (CRC) to metastatic disease. We describe patterns of progression to metastatic disease for an Australian cohort diagnosed with localised or regional CRC.MethodsAll localised and regional CRC cases in the New South Wales Cancer Registry diagnosed during 2000–2007 were followed to December 2011 for subsequent metastases (identified by subsequent disease episode notifications) or CRC death. Cox regression was used to identify factors associated with metastatic progression.ResultsAfter a median 5.3 years follow-up, 26.4% of the 12757 cases initially diagnosed with localised or regional colon cancer had developed metastatic disease, as had 29.5% of the 7154 rectal cancer cases. For both cancer sites, risk of metastatic progression was significantly higher for those initially diagnosed with regional disease (adjusted hazard ratio aHR] 3.49 for colon, 2.66 for rectal cancer), and for older cases (e.g. aHR for >79 years vs <60 years: 1.38 for colon, 1.69 for rectal cancer). Risk of disease progression was significantly lower for females, and varied by histology type. For colon cancer, the risk of disease progression decreased over time. For rectal cancer, risk of metastatic progression was significantly higher for those living in more socioeconomically disadvantaged areas compared with those in the least disadvantaged area.ConclusionsAn understanding of the variation in risk of metastatic progression is useful for planning health service requirements, and can help inform decisions about treatment and follow-up for colorectal cancer patients. |
| |
| Keywords: | Metastatic progression Colorectal cancer Stage at diagnosis Socio-economic status Population-based study Cancer registry Histology type Primary tumour location |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
